Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

ABIONYX Pharma SA (609) Stock Price & Analysis

0 Followers

609 Stock Chart & Stats

€1.55-€0.06(-3.96%)
At close: 5:30 PM GMT+1
€2€2.2€2.4Jun 18Sep 2
Day’s Range
EUR 1.55 - EUR 1.55
52-Week Range
EUR 1.37 - EUR 4.36
Previous Close
EUR 1.62
Volume
N/A
Average Volume (3M)
0
Market Cap
EUR 68.74M
Enterprise Value
EUR 62.06M
Total Cash (Recent Filing)
EUR 26.87M
Total Debt (Recent Filing)
EUR 15.18M
Price to Earnings (P/E)
―
Beta
-0.32
Next Earnings
Mar 16, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Specialized Therapeutic Platform

ABIONYX has a focused biological platform rather than a broad collection of unrelated assets. Its apoA-I and HDL-mimetic approach provides a coherent foundation for developing therapies aimed at severe inflammatory and infectious conditions.

Revenue Above Historical Base

Although recent revenue has declined, the business has progressed beyond the near-zero revenue levels recorded earlier in the period. That higher base indicates some commercial or operating activity and provides a platform from which future candidate-related revenue could develop.

Positive Shareholders' Equity

The company still has positive shareholders' equity, providing a remaining financial base to support research activities and operations. This is a constructive foundation even though the balance has contracted materially and would need stabilization through improved performance or funding.

Bears Say

Persistent Operating Losses

Very large operating losses relative to revenue show that the current business model has not reached economic scalability. Unless revenue expands substantially or the cost structure changes, continued losses can consume capital and limit the resources available for pipeline development.

Sustained Cash Burn

Ongoing operating and free-cash-flow outflows indicate that the company is not yet self-funding its activities. Persistent cash burn increases dependence on external financing and can constrain investment capacity if revenues or margins do not improve materially.

Eroding Equity And Rising Leverage

The combination of sharply lower equity and higher debt-to-equity reduces financial flexibility. A thinner capital base leaves less capacity to absorb further losses, while greater leverage can make future funding and capital allocation more difficult.

ABIONYX Pharma SA News

609 FAQ

What was ABIONYX Pharma SA’s price range in the past 12 months?
ABIONYX Pharma SA lowest stock price was €1.37 and its highest was €4.36 in the past 12 months.
What is ABIONYX Pharma SA’s market cap?
ABIONYX Pharma SA’s market cap is €68.74M.
When is ABIONYX Pharma SA’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were ABIONYX Pharma SA’s earnings last quarter?
ABIONYX Pharma SA released its earnings results on Sep 23, 2026. The company reported -€0.134 earnings per share for the quarter.
Is ABIONYX Pharma SA overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does ABIONYX Pharma SA pay dividends?
ABIONYX Pharma SA does not currently pay dividends.
What is ABIONYX Pharma SA’s EPS estimate?
ABIONYX Pharma SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ABIONYX Pharma SA have?
ABIONYX Pharma SA has 44,067,715 shares outstanding.
What happened to ABIONYX Pharma SA’s price movement after its last earnings report?
ABIONYX Pharma SA reported an EPS of -€0.134 in its last earnings report. Following the earnings report the stock price went up 3.007%.
Which hedge fund is a major shareholder of ABIONYX Pharma SA?
Currently, no hedge funds are holding shares in DE:609
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology